Roche Holding AG (RHHVF)
| 前收市價 | 330.00 |
| 開市 | 324.00 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 324.00 - 330.00 |
| 52 週波幅 | 299.01 - 430.00 |
| 成交量 | |
| 平均成交量 | 8,819 |
| 市值 | 276.8B |
| Beta 值 (5 年，每月) | 0.29 |
| 市盈率 (最近 12 個月) | 17.88 |
| 每股盈利 (最近 12 個月) | 18.40 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 9.97 (3.05%) |
| 除息日 | 2022年3月17日 |
| 1 年預測目標價 | 無 |
- Benzinga
Kiniksa Inks Global License Agreement With Roche For Vixarelimab
Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) has announced a global license agreement with Roche Holdings AG (OTC: RHHBY) and Genentech to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta. "The agreement provides an optimal infrastructure for the further development of vixarelimab. We plan to allocate the non-dilutive capital from this transaction towards synergistic opportunities across our portfolio, including expanding our ARCALYST ca
- Benzinga
Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field
Poseida Therapeutics Inc (NASDAQ: PSTX) has entered into a strategic collaboration and license agreement with Roche Holdings AG (OTC: RHHBY), focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas, and other hematologic indications. Under the agreement, Roche will receive from Poseida either exclu
- Benzinga
Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit
Roche Holdings AG's (OTC: RHHBY) 1H FY22 sales reached CHF 32.3 billion, +5% Y/Y on higher sales of diagnostic tests and pharmaceuticals. Core operating profit increased 9% to CHF 12.7 billion, and EPS up 11% to CHF 11.76. Ocrevus revenue increased 17% to reach CHF 2.9 billion, and Hemlibra sales jumped 30% to CHF 1.83 billion, offsetting a decline in established off-patent cancer medicines Herceptin, Avastin, and Rituxan due to cheaper rival products. Arthritis med Actemra/RoActemra sales decli
